Page 20 - Read Online

Chen et al. Hepatoma Res 2018;4:72 I http://dx.doi.org/10.20517/2394-5079.2018.103 Page 7 of 16

[71]
Kuo et al. , Retro- AFP + US, 1 2002- 318 vs. Asia Cirrhosis: BCLC: NA 3-year: 59.1 Curative:
2010 spec- year 2004 1118 (Taiwan, all 0: 8.2 vs. 3.7 vs. 29.3 45.6 vs.
tive China) HBV: 48.7 A: 60.4 vs. 23.1 22.7
vs. 47.1 B: 21.7 vs. 35.2 TACE: 47.2
HCV: 38.1 C: 6.9 vs. 30.9 vs. 38.2
vs. 33.4 (P < 0.001) Other: 7.2
vs. 39.1
Noda et al. [61] , Retro- Imaging (US/ 2001- 124 vs. Asia (Ja- HCV: all Milan criteria: NA 1-year: 90 Curative:
2010 spec- CT/MRI) 2007 116 pan) Cirrhosis: 88 vs. 44 vs. 50 80 vs. 45
tive 73 vs. 64.7 (P < 0.001) 3-year: 73
vs. 34
5-year: 54
vs. 9
Pascual et al. [72] , Retro- US + AFP ev- 1996- 117 vs. 173 Europe Cirrhosis: Tumor size: < 5 NA Mean LTx: 15 vs. 3
2008 spec- ery 6 months 2005 (Spain) all cm: 60 vs. 24 survival PEI/RF:
tive Alcohol: 21 > 5 cm: 9 vs. (months): 31.6 vs. 12.1
vs. 35 28 27 vs. 6 TACE: 39
HCV: 61 vs. Multifocal: 14 vs. 20
35 vs. 32
HBV: 3 vs. 6
Others: 10
vs. 13
Tanaka et al. [73] , Retro- US + AFP, 6 1991-2003 182 vs. Asia (Ja- HCV: all Milan: NA Median Resection:
2006 spec- months 202 pan) Cirrhosis: 86 vs. 50 survival 6 vs. 12
tive 84 vs. 76 (year): PEI/RFA:
4.7 vs. 3.1 60 vs. 34
(P < 0.001) TACE: 20
vs. 42
3-year: 67 Chemo: 3
vs. 51 vs. 9
5-year: 46 (P < 0.001)
vs. 32
Toyoda et al. [74] , Retro- AFP/DCP +/- 1968- 1050 vs. Asia (Ja- NA Stage I: 24 vs. NA 3-year: 51.4 LTx: 21.7 vs.
2006 spec- imaging 2004 591 pan) 3.6 vs. 27.1 5.1
tive Stage II: 33.6 5-year: 35.9 Resection:
vs. 16 vs. 18.6 22.6 vs. 9
Stage III: 24 vs. TACE: 34.1
15.7 vs. 27.2
Stage IV: 18.2 Others: 7
vs. 64.6 vs. 19.8
Ando et al. [75] , Retro- AFP and 1995- 392 vs. Asia (Ja- Cirrhosis: Early HCC: NA 3-year: 62 Curative:
2006 spec- imaging 2000 182 pan) NA 73 vs. 26 vs. 38 56.9 vs. 26
tive HCV: 87 vs. Supportive:
74 0 vs. 7
HBV: 8.7 vs.
17
e
e
Trevisani et al. [24] , Retro- US + AFP 1998-2001 158 vs. Europe Cirrhosis: Tumor ≤ 3 cm : NA Median Resection :
2004 spec- every 6-12 205 (Italy) all 68.7 vs. 49.3 survival 8.4 vs. 2.9
tive months HBV: 9.5 vs. vs. 6.7 (months, vs. 0
8.3 Multifocal: lead-time TACE: 28.6
e
HCV: 67.1 11.1 vs. 15.9 vs. corrected) : vs. 17.6 vs.
vs. 60.5 22.4 24 vs. 21 vs. 20
Alcohol: 5.7 Advanced: 7 Others:
vs. 11.7 29.7 vs. 60.9 27.3 vs.
vs. 74.6 42.6 vs.
69.2
Yu et al. [18] , Retro- US 1996-1997 164 vs. Asia Cirrhosis: TNM NA Unadj OR of Resection:
2004 spec- 516 (Taiwan, 91.9 vs. I: 66.2 vs. 19.3 survival at 53.5 vs. 34
tive China) 68.2 II: 27.2 vs. 37.2 1-year: 3.57 (P <
HBV: III: 3.7 vs. 28.0 (5.26 - 0.0001)
67.7 vs. IV: 2.9 vs. 14.6 2.38) TACE: 35.1
53.6 2-year: 3.7 vs. 29.9
HCV: (5.26 -
43.9 vs. 2.56)
31.3 3-year: 3.57
(5.26 -
2.44)